Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biomarkers for individualized dosage adjustments in immunosuppressive therapy using calcineurin inhibitors after organ transplantation.

Acta pharmacologica Sinica - 1 Feb 2019

Fu Rao, Tajima Soichiro, Suetsugu Kimitaka, Watanabe Hiroyuki, Egashira Nobuaki, Masuda Satohiro

Abstract excerpt

Calcineurin inhibitors (CNIs), such as cyclosporine A and tacrolimus, are widely used immunosuppressive agents for the prevention of post-transplantation rejection and have improved 1-year graft survival rates by up to 90%. However, CNIs can induce severe reactions, such as acute or chronic allograft nephropathy, hypertension, and neurotoxicity. Because CNIs have varied bioavailabilities, narrow therapeutic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ATP Binding Cassette Transporter, Subfamily B, Member 1
Share to Biomarkers, Pharmacological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Calcineurin Inhibitors

Share to Cytochrome P-450 CYP3A

Share to Drug Monitoring

Share to Graft Rejection

Share to Lipocalin-2

Share to Organ Transplantation

Source

Open in PubMed Open full text

Identifiers

PMID: 29950613
DOI: 10.1038/s41401-018-0070-2
PMCID: PMC6329804

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biomarkers for individualized dosage adjustments in immunosuppressive therapy using calcineurin inhibitors after organ transplantation.PMID 29950613Read ↗

Pharmacogenetics and drug-induced nephrotoxicity in renal transplant recipientsSemantic proximity Read ↗

Personalized immunosuppression after kidney transplantation.Semantic proximity Read ↗

Genetic and clinical determinants of early, acute calcineurin inhibitor-related nephrotoxicity: results from a kidney transplant consortium.Semantic proximity Read ↗

Pharmacogenetics of calcineurin inhibitors in renal transplantation.Semantic proximity Read ↗

Trends in Precision Medicine and Pharmacogenetics as an Adjuvant in Establishing a Correct Immunosuppressive Therapy for Kidney Transplant: An Up-to-Date Historical OverviewSemantic proximity Read ↗

Risk factors for calcineurin inhibitor nephrotoxicity after renal transplantation: a systematic review and meta-analysis.Semantic proximity Read ↗

Pharmacogenetics in immunosuppressants: impact on dose requirement of calcineurin inhibitors in renal and liver pediatric transplant recipients.Semantic proximity Read ↗

Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks.Semantic proximity Read ↗

Biomarkers of immunosuppressant organ toxicity after transplantation: status, concepts and misconceptions.Semantic proximity Read ↗

Utilization of an EMR-biorepository to identify the genetic predictors of calcineurin-inhibitor toxicity in heart transplant recipients.Semantic proximity Read ↗

Understanding and Preventing Adverse Effects of Tacrolimus Metabolization in Transplant Patients.Semantic proximity Read ↗

Recent advances in precision medicine for individualized immunosuppression.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.